export const personas = [
  {
    id: 1,
    name: 'Vangelis Vergetis, PhD',
    title: 'CEO and board member',
    filters: [
      { position: 'all', order: 7 },
      { position: 'board', order: 5 },
      { position: 'executive', order: 1 },
    ],
    img: 'assets/images/Vangelis_vergetis.png',
    linkedin: 'https://www.linkedin.com/in/vangelisvergetis',
    bio: `
      <p>
        Vangelis has been working in the intersection 
        of healthcare, technology, and data science 
        for more than 15 years.
      </p>
      <p>
        He started his career as a consultant at McKinsey and at Hakluyt 
        for about a douzen years, advising biopharmaceutical executives 
        on several topics - particularly in launching drugs across 
        disease areas, and in designing and putting in 
        place their commercial models and infrastructure. 
      </p>
      <p>
        
      </p>
      <p>
        Immediately prior to Epikast, Vangelis was the 
        co-founder and CEO of Intelligencia, a software 
        company that utilizes AI to assess and reduce 
        the risk of clinical trials. He currently serves 
        as a board advisor to the company.
      </p>
      <p>
        He is a board member and member of the executive committee 
        at the Alliance for AI in Healthcare (AAIH), 
        and a former member of the advisory board for 
        Cornell's Bowers College of Computing &amp; 
        Information Science (CIS).
      </p>
      <p>
        Vangelis holds a 
        PhD in Electrical Engineering from the University 
        of Pennsylvania, and a BS in 
        Computer Science from Cornell.
      </p>
    `,
  },
  {
    id: 2,
    name: 'Stelios Papadopoulos, PhD',
    title: 'Chairman of the board',
    filters: [
      { position: 'all', order: 5 },
      { position: 'board', order: 1 },
    ],
    img: 'assets/images/Stelios_papadopoulos.jpg',
    linkedin: null,
    bio: `
      <p>
        Stelios brings more than four decades of experience in the 
        biopharmaceutical industry in various roles: as a company founder, 
        executive, investment banker, and leader in the global healthcare 
        sector.
      </p>
      <p>
        Stelios is Chairman of the Board of Directors of Biogen, Inc., 
        Exelixis, Inc., and Regulus Therapeutics, Inc. He is a co-founder 
        of Exelixis, as well as co-founder and former Chairman of Anadys 
        Pharmaceuticals (acquired by Hoffman–La Roche in 2011) and 
        Cellzome (acquired by GlaxoSmithKline in 2012). In 
        the not-for-profit sector, Stelios is a member of the 
        Board of Visitors of Duke Medicine, a member of the Global 
        Advisory Board of the Duke Institute for Health Innovation, 
        and co-founder and Chairman of Fondation Santé 
        (<a href="www.fondationsante.org">www.fondationsante.org</a>), a foundation providing 
        research support and mentorship to biomedical 
        scientists in Greece and Cyprus.
      </p>
      <p>
        Stelios spent six years (2000-06) at Cowen & Co., LLC, most 
        recently as Vice Chairman, where as an investment banker he 
        focused on the biotech and pharma sectors. Prior to joining 
        Cowen, he spent 13 years as an investment banker at PaineWebber, 
        Incorporated where he was most recently Chairman of 
        PaineWebber Development Corp., a PaineWebber subsidiary 
        focusing on biotechnology. He joined PaineWebber in 1987 
        from Drexel Burnham Lambert where he was an analyst in 
        the Equity Research Department covering the biotechnology industry. 
        Prior to Drexel, he was the biotechnology analyst of Donaldson, 
        Lufkin & Jenrette. Stelios has received multiple honors and 
        awards for his work in the biopharma industry as a company 
        founder, adviser, and financier.
      </p>
      <p>
        Before coming to Wall Street, Stelios was on the faculty of the 
        Department of Cell Biology at New York University School of 
        Medicine. Stelios holds an M.S. in physics, a Ph.D. in biophysics 
        and an M.B.A. in finance, all from New York University.
      </p>
    `,
  },
  {
    id: 3,
    name: 'Daphne Karydas',
    title: 'Board member',
    filters: [
      { position: 'all', order: 1 },
      { position: 'board', order: 2 },
    ],
    img: 'assets/images/Daphne.jpg',
    linkedin: 'https://www.linkedin.com/in/daphne-karydas-493b17/',
    bio: `
      <p>
        Daphne has over 25 years of experience in 
        financial and operations leadership roles 
        focused in the biopharmaceutical industry, 
        where she has brought an interdisciplinary 
        approach to implementing growth strategies 
        for biopharmaceutical and asset 
        management companies.
      </p>
      <p>
        She is currently the COO and CFO of Flare 
        Therapeutics, which she joined in October 2021. 
        Prior to Flare she was the CFO of Syndax 
        Pharmaceuticals, and also served as SVP of 
        Strategy and Corporate Financial Planning & 
        Analysis at Allergan plc, where she oversaw 
        the company’s long-term financial and 
        business strategy until its acquisition 
        by Abbvie in May 2020. She joined 
        Allergan in April 2017 as the SVP of 
        Global Investor Relations and Strategy, 
        leading engagement with the investment 
        community and business strategy development.
      </p>
      <p>
        Prior to her senior operating roles in the industry, 
        Daphne served as Executive Director and Senior 
        Healthcare Analyst at J.P. Morgan Asset Management. 
        Previously, she was a Portfolio Manager and Senior 
        Healthcare Analyst at The Boston Company Asset 
        Management, a BNY Mellon company. Earlier in 
        her career she was a VP at Goldman Sachs Asset 
        Management focused on healthcare, as well as a 
        member of Goldman Sachs’ healthcare investment 
        banking team. Before joining Goldman Sachs she 
        was a Project Chemical Engineer at Merck, 
        where she focused on process development 
        for novel vaccines.
      </p>
      <p>
        Daphne received a BA and MS in chemical engineering 
        from MIT and an MBA from Harvard Business School.
      </p>
    `,
  },
  {
    id: 4,
    name: 'Dimitris Papalexopoulos',
    title: 'Board member',
    filters: [
      { position: 'all', order: 6 },
      { position: 'board', order: 4 },
    ],
    img: 'assets/images/Dimitris_Papalexopoulos.jpg',
    linkedin: null,
    bio: `
      <p>
        Dimitri is Chairman of Titan Cement Group, a cement 
        and building materials producer active since 1902. 
        The group directly employs about 5,500 people, 
        operates cement plants in 10 countries, and is 
        active in many more. Prior to joining Titan in 1989, 
        Dimirti started his career as a business consultant 
        for McKinsey & Company in the USA and Germany.
      </p>
      <p>
        He is Chairman of the Board of the Hellenic Federation 
        of Enterprises (SEV), Vice-Chairman of the European 
        Round Table for Industry (ERT) and chairs the ERT’s 
        Energy Transition & Climate Change Committee. 
        He is a member of the Board of the Foundation for 
        Economic and Industrial Research (IOBE), the 
        Hellenic Foundation for European and Foreign Policy 
        (ELIAMEP), and of Endeavor Greece.
      </p>
      <p>
        He holds a M.Sc. 
        in Electrical Engineering from the Swiss Federal 
        Institute of Technology (ETHZ) and an MBA 
        from Harvard Business School.
      </p>
    `,
  },
  {
    id: 5,
    name: 'Mike Krzan',
    title: 'Advisor',
    filters: [
      { position: 'all', order: 3 },
      { position: 'advisors', order: 1 },
    ],
    img: 'assets/images/Mike_Krzan.jpg',
    linkedin: 'https://www.linkedin.com/in/mike-krzan',
    bio: `
      <p>
        Mike brings a lifetime of experience in building and 
        running high-performing patient services organizations, 
        having spent more than 20 years in the space. He led 
        Biogen’s patient services center in North Carolina 
        for more than a decade, and prior to that was a SVP 
        for member services and pharmacy operations at Medco. 
      </p>
      <p>
        While at Biogen, Mike was a member of the US Senior 
        Leadership Team, developed and set the direction for 
        the patient services organization to support $8B of 
        revenue, launched seven products (including a blockbuster 
        drug and an orphan drug), and collaborated with 
        field sales leaders to identify trends, define 
        tactics for improved performance, and ensure national 
        team alignment. 
      </p>
      <p>
        He holds a BS in Pharmacy 
        from Duquesne University.
      </p>
    `,
  },
  {
    id: 6,
    name: 'Angelos Kapsimanis',
    title: 'Chief Technology Officer',
    filters: [
      { position: 'all', order: 2 },
      { position: 'executive', order: 2 },
    ],
    img: 'assets/images/Angelos.png',
    linkedin: 'https://www.linkedin.com/in/angeloskapsimanis',
    bio: `
      <p>
        Angelos has been working in the tech industry for more than two decades, 
        with experience across 65+ countries. He has led teams across multiple 
        verticals and industries, with a focus on data, machine learning, and AI.
      </p>
      <p>
        He has spent a significant amount of his career in the FinTech industry, 
        helping Klarna to expand globally and reach a valuation of $70B. 
        While at Klarna he managed teams interspersed across the planet, 
        focusing on analytics, machine learning, real-time decision making, 
        and risk management. Prior to Klarna, Angelos built the whole technology 
        function for Motionlogic, an analytics company that is part of the Deutsche 
        Telekom group, and helped it achieve a 52-fold increase in revenues in 3 years. 
        He bootstrapped and successful led to exit Aton Solar, which developed embedded 
        systems and telemetry solution for solar energy facilities.
      </p>
      <p>
        He holds an MS in Machine Learning from Georgia Tech, a second Masters 
        in Computational Statistics from De Montfort University in the UK, and a 
        BS in Industrial Informatics in the University of Applied Sciences in Kavala, Greece.
      </p>
    `,
  },
  {
    id: 7,
    name: 'Oleg Nodelman',
    title: 'Board member',
    filters: [
      { position: 'all', order: 4 },
      { position: 'board', order: 3 },
    ],
    img: 'assets/images/Oleg.png',
    linkedin: 'https://www.linkedin.com/in/oleg-nodelman-375131',
    bio: `
      <p>
        Oleg is the founder and Portfolio Manager of EcoR1 Capital LLC, 
        a biotech-focused investment fund established in 2013, 
        which invests in companies at all stages of research and 
        development. With nearly twenty years of experience in 
        biotech investing, he has expertise in all aspects of 
        investment management and deep roots in the biotech 
        and scientific communities. 
      </p>
      <p>
        Before founding EcoR1, Oleg was a portfolio manager at BVF 
        Partners, one of the first hedge funds dedicated to the 
        biotechnology sector. He currently serves as a Board 
        Member for Prothena Biosciences (NASDAQ: PRTA), AnaptysBio 
        (Nasdaq: ANAB), Nuvation Bio (Nasdaq: NUVB), Panacea 
        (Nasdaq: PANA), Scorpion Therapeutics, Aktis Oncology, 
        ReCode, and Paratus. 
      </p>
      <p>
        Oleg holds a BS in Foreign Service with a concentration in 
        Science and Technology from Georgetown University.
      </p>
    `,
  },
];
